How do bisphosphonates inhibit bone metastasis in vivo?

@article{Fournier2010HowDB,
  title={How do bisphosphonates inhibit bone metastasis in vivo?},
  author={P. Fournier and V. Stresing and F. Ebetino and P. Cl{\'e}zardin},
  journal={Neoplasia},
  year={2010},
  volume={12 7},
  pages={
          571-8
        }
}
Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and have demonstrated clinical utility in the treatment of patients with osteolytic bone metastases. They also exhibit direct antitumor activity in vitro and can reduce skeletal tumor burden and inhibit the formation of bone metastases in vivo. However, whether such effects are caused by a direct action of bisphosphonates on tumor cells or indirectly through inhibition of bone resorption remains unclear. To address… Expand
Bone metastasis in breast cancer: the story of RANK-ligand.
Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5‐Fluorodeoxyuridine‐Alendronate in a Preclinical Model of Breast Cancer Bone Metastases
  • C. Schem, R. Tower, +11 authors S. Tiwari
  • Medicine
  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2017
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Mechanisms of osteolytic bone metastases in breast carcinoma
Angiostatin Inhibits Bone Metastasis Formation in Nude Mice through a Direct Anti-osteoclastic Activity*
Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid
...
1
2
3
4
...